Scarica l'app Stockscreener
262.80
0.37%
0.98
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$261.82
Aprire:
$265.2
Volume 24 ore:
161.77K
Relative Volume:
0.67
Capitalizzazione di mercato:
$7.09B
Reddito:
$2.58B
Utile/perdita netta:
$759.90M
Rapporto P/E:
9.4137
EPS:
27.9168
Flusso di cassa netto:
$374.60M
1 W Prestazione:
-2.61%
1M Prestazione:
+2.43%
6M Prestazione:
-6.26%
1 anno Prestazione:
+7.26%
Intervallo 1D:
$261.38
$270.00
Intervallo di 1 settimana:
$259.56
$272.04
Portata 52W:
$211.43
$343.12
Bio Rad Laboratories Inc Stock (BIO) Company Profile
Nome
Bio Rad Laboratories Inc
Settore
Industria
Telefono
(510) 724-7000
Indirizzo
1000 ALFRED NOBEL DRIVE, HERCULES
Compare BIO vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
262.80 | 7.09B | 2.58B | 759.90M | 374.60M | 27.92 |
|
ABT
Abbott Laboratories
|
108.03 | 187.72B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
336.77 | 128.88B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
87.14 | 111.88B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.13 | 102.58B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
81.81 | 47.52B | 6.07B | 1.06B | 1.34B | 1.8063 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-08-28 | Iniziato | Wells Fargo | Equal Weight |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2024-04-03 | Downgrade | Citigroup | Buy → Neutral |
| 2023-12-07 | Iniziato | UBS | Buy |
| 2023-06-16 | Iniziato | Wells Fargo | Overweight |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-01-28 | Reiterato | Citigroup | Buy |
| 2020-01-08 | Iniziato | Wells Fargo | Overweight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2018-10-17 | Iniziato | Goldman | Buy |
| 2018-09-20 | Iniziato | Morgan Stanley | Equal-Weight |
| 2018-02-16 | Downgrade | CL King | Buy → Neutral |
| 2017-07-13 | Iniziato | Wells Fargo | Outperform |
| 2017-06-28 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2017-01-18 | Iniziato | Deutsche Bank | Hold |
| 2016-10-13 | Iniziato | CL King | Buy |
| 2015-05-06 | Reiterato | Jefferies | Buy |
| 2009-12-18 | Iniziato | Maxim Group | Buy |
| 2009-11-06 | Iniziato | Jefferies & Co | Buy |
| 2009-07-17 | Iniziato | Soleil | Buy |
| 2007-09-26 | Iniziato | Banc of America Sec | Buy |
| 2007-02-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
Mostra tutto
Bio Rad Laboratories Inc Borsa (BIO) Ultime notizie
10,425 Shares in Bio-Rad Laboratories, Inc. $BIO Purchased by Magnetar Financial LLC - MarketBeat
Bio-Rad Laboratories, Inc. $BIO Shares Purchased by Natixis Advisors LLC - MarketBeat
Capital Research Global Investors Makes New Investment in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Molecular Diagnostics Market Outlook: Set to Grow at 10%+ CAGR Through 2031 as Precision Medicine and Genetic Testing Advance, Says Mordor Intelligence - GlobeNewswire Inc.
Assessing Whether Bio-Rad Laboratories (BIO) Looks Undervalued After Recent Share Price Softness - Yahoo Finance
Bio-Rad Laboratories Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Chipmakers Recap: Is Bio Rad Laboratories Inc stock forming a triangle patternJuly 2025 Intraday Action & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Dimensional Fund Advisors LP Purchases 63,370 Shares of Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Bio-Rad Laboratories Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
Published on: 2026-03-07 12:19:08 - baoquankhu1.vn
Bio-Rad outlines flat to 1% currency-neutral revenue growth for 2025 while expanding ddPCR partnerships - MSN
TD Asset Management Inc Purchases 7,386 Shares of Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Bio-Rad Laboratories, Inc. $BIO Shares Bought by GW&K Investment Management LLC - MarketBeat
Portfolio Shifts: Will Bio Rad Laboratories Inc outperform its industry peersQuarterly Risk Review & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Teachers Retirement System of The State of Kentucky Has $10.22 Million Stake in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Analysts Issue Forecasts for BIO FY2028 Earnings - MarketBeat
Fisher Asset Management LLC Lowers Stock Position in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Medical Dry Fluorescence Immunoassay Analyzer Market Is Going - openPR.com
Automatic Blood Group Diagnostic Instrument Market Is Going - openPR.com
Assessing Bio-Rad (BIO) Valuation After Mixed Share Price Performance And Recurring Revenue Shift - simplywall.st
Roubaix Capital LLC Buys Shares of 8,112 Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Zacks Research Has Bearish Estimate for BIO Q1 Earnings - MarketBeat
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating a 16.36% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Digital PCR Market to Reach US$ 14.37 Billion by 2033 at 9.8% CAGR; - openPR.com
Artisan Partners Limited Partnership Has $24.22 Million Position in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Westfield Capital Management Co. LP Increases Stock Holdings in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Is It Time To Reconsider Bio-Rad Laboratories (BIO) After Its Prolonged Share Price Slump - Sahm
Bio-Rad Laboratories, Inc. $BIO Shares Sold by Vanguard Group Inc. - MarketBeat
A Look At Bio Rad Laboratories (BIO) Valuation After Recent Share Price Weakness - simplywall.st
(BIO) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Molecular Biology Analyzers Market Set to Boom by 2033: - openPR.com
Microfluidics Research Report 2026-2035: A $20.73 Billion - GlobeNewswire
Microfluidics Research Report 2026-2035: A $20.73 Billion Market by 2030 with Thermo Fisher Scientific, PerkinElmer, Dolomite, Agilent Technologies, Bio-Rad Laboratories, and Fluidigm Leading - Yahoo Finance
Bio-Rad Laboratories (NYSE:BIO.B) Shares Pass Below 200-Day Moving AverageTime to Sell? - MarketBeat
Weekly Earnings: What is the long term forecast for Bio Rad Laboratories Inc stockJuly 2025 Reactions & High Win Rate Trade Alerts - baoquankhu1.vn
International Markets and Bio-Rad (BIO): A Deep Dive for Investors - Yahoo Finance
Bio-Rad Laboratories, Inc. $BIO Shares Sold by ICICI Prudential Asset Management Co Ltd - MarketBeat
Blood Grouping Reagents Market Top Key Players -Grifols, Roche, - openPR.com
Hemocytometer Market Is Going to Boom Rapidly With Top Key - openPR.com
CenterBook Partners LP Has $2.56 Million Holdings in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
4 Undervalued Life Sciences Tools & Services Stocks for Thursday, February 19 - AAII
Bio-Rad Updates Investors on Sartorius Strategic Investment Metrics - TipRanks
Sartorius 2025 results summarized in Bio-Rad (NYSE: BIO) update - Stock Titan
Bio-Rad Laboratories, Inc. (BIO) achieves modest revenue growth and robust free cash flow growth - MSN
Bio-Rad Laboratories, Inc. (BIO) Achieves Modest Revenue Growth and Robust Free Cash Flow Growth - Finviz
Risk Hedge: Is RBOT still a buy after recent gains2025 Institutional Moves & Stock Timing and Entry Methods - baoquankhu1.vn
Bio-Rad's Q4 Earnings Miss Estimates, Revenues Surpass, Stock Down - Yahoo Finance
Protein Engineering Market to Grow at 15.6% CAGR from 2025 - openPR.com
Bio-Rad Laboratories, Inc. (NYSE:BIO) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Protein Engineering Market Is Going to Boom Rapidly With Top Key - openPR.com
Bio-Rad's Timing for Revenue Growth Recovery Remains Uncertain - Morningstar
Bio Rad Laboratories Inc Azioni (BIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.66%
1.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):